CT
CTTH.US CTT Pharmaceutical Holdings Inc
- Market cap
- USD 3.28M
- P/E
- -
- P/B
- 125.92x
- ROE
- -767.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CTTH.US undervalued?
Graham numberThe Graham number of CTT Pharmaceutical Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CTT Pharmaceutical Holdings Inc fundamental analysis
No fundamental analysis for CTT Pharmaceutical Holdings Inc yet.
CTT Pharmaceutical Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CTT Pharmaceutical Holdings Inc
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered dissolvable strip. The co…
Full company profileCTT Pharmaceutical Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CTT Pharmaceutical Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 40.0K | 25.0K | 49.2K | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 40.0K | 25.0K | 49.2K | - | - | -6.40K | -6.40K | -6.40K | -6.43K | -6.81K |
| Operating Income | -640K | -1.37M | -1.71M | -591K | -584K | -148K | -109K | -42.1K | -250K | -127K | -198K |
| EBITDA | -643K | -1.38M | -1.71M | -414K | -380K | 104K | -44.7K | -35.7K | -244K | -120K | -192K |
| Net Income | -643K | -1.38M | -1.73M | -586K | -586K | -133K | -53.4K | -42.2K | -210K | -156K | -200K |
| EPS | -0.03 | -0.04 | -0.04 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 99.6K | 187K | 781K | 573K | 376K | 108K | 93.9K | 79.3K | 73.0K | 86.2K | 67.4K |
| Total Liabilities | 205K | 276K | 281K | 450K | 663K | 102K | 4.61K | 19.3K | 40.9K | 31.0K | 41.4K |
| Shareholders' Equity | -106K | -89.6K | 500K | 123K | -287K | 5.28K | 89.3K | 60.0K | 32.2K | 55.2K | 26.0K |
| Cash & Short-term Investments | 99.6K | 137K | 780K | 389K | 202K | 102K | 8.10K | - | 114.00 | 15.4K | 31.00 |
| Total Debt | 54.8K | 58.4K | - | - | - | - | - | 10.9K | 16.9K | 18.8K | 19.4K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.06K | -145K | -300K | -390K | -186K | -600K | -139K | -21.1K | -228K | -75.5K | -52.3K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 | 1.00 | 3.00 | 0.00 |
| Free Cash Flow | -6.06K | -145K | -300K | -390K | -186K | -600K | -139K | -21.1K | -33.9K | -75.5K | -52.3K |
| Ratios | |||||||||||
| ROE | - | - | -345.5% | -477.3% | - | -2,520.8% | -59.9% | -70.3% | -652.5% | -282.6% | -767.3% |
| ROA | -645.4% | -740.3% | -221.1% | -102.2% | -155.9% | -123.5% | -56.9% | -53.2% | -287.5% | -181.0% | -296.3% |
| Net Profit Margin | - | -3,452.5% | -6,912.0% | -1,191.0% | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | - | - | 0.18x | 0.53x | 0.34x | 0.75x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CTT Pharmaceutical Holdings Inc dividends
CTT Pharmaceutical Holdings Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Aug 28, 2015.
Who owns CTT Pharmaceutical Holdings Inc
- Insiders 50.35%
- Institutions 0.00%
- Public & others 49.65%
- Shares outstanding 58.7M
- Free float 28.1M
CTT Pharmaceutical Holdings Inc company profile
- Company name
- CTT Pharmaceutical Holdings Inc
- Ticker
- CTTH.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1
- Fiscal year end
- December
- Address
- 3853 Northdale Blvd, Tampa, FL, United States, 33624
- Phone
- 813-606-0060
- Website
- cttpharmaceuticals.com
About CTT Pharmaceutical Holdings Inc
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company's technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered dissolvable strip. The company is based in Tampa, Florida.
CTT Pharmaceutical Holdings Inc management
3- Mr. Ryan KhouriChief Executive Officer · born 1980
- Dr. Pankaj Modi M.D., Ph.D.Founder & Consultant · born 1955
- Mr. Marc LakmaakerSpecial Advisor & Senior VP of Commercial Development